Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study DOI Creative Commons

Athitaya Luangnara,

Salin Kiratikanon, Thanika Ketpueak

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Oct. 20, 2022

Although immune checkpoint inhibitors (ICIs) have become the frontline treatment option for patients with various advanced cancers due to improved survival, they can be associated a spectrum of cutaneous immune-related adverse events (cirAEs). However, little is known regarding occurrence and patterns cirAE-related ICI therapy in different races other than white populations. Therefore, we investigated incidence factors cirAEs among cancer northern Thailand.A referral-center-based ambispective cohort study was conducted from January 1, 2017, March 31, 2021. Based on linked database merged patient-level data, adult pathologically confirmed who were diagnosed received regardless type followed up through August 2021, included. All based clinical evaluation ascertainment by board-certified dermatologist. The confidence intervals (CIs) across cancer- therapy-specific groups estimated. Factors evaluated using multivariable modified Poisson regression estimate risk ratios (RRs) 95% CIs.The included 112 (67 men [59.8%]; mean age, 65.0 [range, 31.0-88.0] years), mainly lung (56.3%), liver (19.6%). overall 32.1% (95% CI, 24.1-41.4); however, there no substantial difference sex, type, or individual therapy. two identified prognostic age >75 years (adjusted RR, 2.13; 1.09-4.15; P=0.027) pre-existing chronic kidney disease stages 3-4 3.52; 2.33-5.31; P<0.001).The Thai comparable that Early identification, particularly elderly those CKD, should implemented practice help optimize therapeutic decision-making patient health outcomes.

Language: Английский

Itch: Epidemiology, clinical presentation, and diagnostic workup DOI Creative Commons
Youkyung S. Roh, Justin Choi, Nishadh Sutaria

et al.

Journal of the American Academy of Dermatology, Journal Year: 2021, Volume and Issue: 86(1), P. 1 - 14

Published: Aug. 21, 2021

Language: Английский

Citations

72
Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study DOI Creative Commons
Thomas K. Le, Isabelle Brown, Rebecca Goldberg

et al.

Journal of Investigative Dermatology, Journal Year: 2022, Volume and Issue: 142(11), P. 2896 - 2908.e4

Published: May 20, 2022

Language: Английский

Citations

18
Advancing Precision Medicine: Uncovering Biomarkers and Strategies to Mitigate Immune-Related Adverse Events in Immune Checkpoint Inhibitors Therapy DOI Creative Commons

K L Nityashree,

P. Rachitha,

Shilpa Hanchinmane

et al.

Toxicology Reports, Journal Year: 2025, Volume and Issue: unknown, P. 102035 - 102035

Published: April 1, 2025

Language: Английский

Citations

0
Positive Osimertinib Patch Test in a Bullous Lichenoid Drug Reaction DOI
Clarisse Marcombes,

Kamar Bel Hareth,

Héloïse Mazoyer

et al.

Contact Dermatitis, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

Citations

0
Mucocutaneous adverse events to immune checkpoint inhibitors DOI Creative Commons
Fiorinda F. Muhaj,

Padmavathi V. Karri,

Wylie Moody

et al.

Frontiers in Allergy, Journal Year: 2023, Volume and Issue: 4

Published: March 2, 2023

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. Since the approval of ipilimumab in 2011, a total nine ICIs gained indications for various solid and hematologic malignancies. The expanding use oncology underscores need diagnosis treatment expertise immune related adverse events (irAE). Cutaneous toxicities are earliest most common irAE this class In addition to more frequent reactions including vitiligo, lichenoid dermatitis, psoriasiform other less skin bullous dermatoses, neutrophilic autoimmune dermato-rheumatologic diseases been reported. Even though than 3% cutaneous irAEs (irCAEs) classified as grade 3 or higher events, irCAEs can greatly impact quality life. Appropriate management is critical avoid unwarranted interruptions discontinuation lifesaving immunotherapy.

Language: Английский

Citations

6
Immune cell subsets in interface cutaneous immune‐related adverse events associated with anti‐PD ‐1 therapy resemble acute graft versus host disease more than lichen planus DOI Creative Commons

Guillermo E. Almodovar Cruz,

Genevieve J. Kaunitz,

Julie E. Stein

et al.

Journal of Cutaneous Pathology, Journal Year: 2022, Volume and Issue: 49(8), P. 701 - 708

Published: April 21, 2022

Checkpoint immunotherapy is frequently associated with cutaneous immune-related adverse events (cirAEs), and among those, the most common subtype shows interface reaction patterns that have been likened to lichen planus (LP); however, acute graft versus host disease (aGVHD) may be a closer histopathologic comparator. We used quantitative pathology compare immunologic composition of anti-PD-1-associated reactions LP aGVHD assess for similarities differences between these eruptions.Immunohistochemistry CD4, CD8, CD68, PD-1, PD-L1 was performed on formalin-fixed paraffin-embedded tissue from patients anti-PD-1 cirAEs (n = 4), 9), or 5). Densities immune cell subsets expressing each marker were quantified using HALO image analysis module. Plasma eosinophil density routine H&E slides.Specimens showed equivalent total densities those aGVHD. Patients higher infiltration, absolute T-cell densities, increased CD8 proportion, reduced histiocytic component. The cases highest plasma counts all aGVHD.The in more closely resembles response seen than within our cohort. This warrants look via advanced analytics implications shared pathogenesis potential treatment options.

Language: Английский

Citations

4
Lesions in the oral mucosa associated with the use of checkpoint inhibitors: A bibliometric and critical review DOI Open Access
Lucas Alves Jural, Daniella Estanho,

Juliana da Silva Rangel Pereira

et al.

Special Care in Dentistry, Journal Year: 2023, Volume and Issue: 44(2), P. 300 - 313

Published: June 7, 2023

Immune-related adverse events (irAEs) linked to the use of immune checkpoint inhibitors (ICIs) have become increasingly frequent. To perform a bibliometric and critical review general panorama publications on oral mucosal lesions (OML) associated with ICIs.

Language: Английский

Citations

2
Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies DOI
Christopher J. Fay,

Samantha Jakuboski,

Beth N. McLellan

et al.

American Journal of Clinical Dermatology, Journal Year: 2023, Volume and Issue: 24(5), P. 765 - 785

Published: July 3, 2023

Language: Английский

Citations

2
Immune checkpoint inhibitor-induced cutaneous toxicities: a review of histopathologic and clinical features DOI

J Martel,

Hannah L. Hanania, Anisha B. Patel

et al.

Human Pathology, Journal Year: 2023, Volume and Issue: 140, P. 144 - 172

Published: May 2, 2023

Language: Английский

Citations

1
Cutaneous immune-related adverse event burden and effect on immunotherapy: A retrospective review of the experience at a tertiary care immunotherapy center DOI Open Access
Thomas K. Le,

Elizabeth Schoenberg Newland,

Isabelle Brown

et al.

Journal of the American Academy of Dermatology, Journal Year: 2023, Volume and Issue: 90(3), P. 648 - 650

Published: Nov. 17, 2023

Language: Английский

Citations

1